These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 25628732)

  • 1. Oral disease-modifying therapies for multiple sclerosis.
    Kim W; Zandoná ME; Kim SH; Kim HJ
    J Clin Neurol; 2015 Jan; 11(1):9-19. PubMed ID: 25628732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
    Gold R
    CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview.
    Deleu D; Mesraoua B; Canibaño B; Melikyan G; Al Hail H; El-Sheikh L; Ali M; Al Hussein H; Ibrahim F; Hanssens Y
    Curr Med Res Opin; 2019 Feb; 35(2):249-260. PubMed ID: 29764226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.
    Longbrake EE; Cross AH; Salter A
    Mult Scler J Exp Transl Clin; 2016; 2():. PubMed ID: 28280599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral treatments in multiple sclerosis].
    Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.
    Gasperini C; Ruggieri S; Pozzilli C
    Ther Clin Risk Manag; 2010 Sep; 6():391-9. PubMed ID: 20856685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of oral immunomodulatory agents in the management of multiple sclerosis.
    Nicholas R; Giannetti P; Alsanousi A; Friede T; Muraro PA
    Drug Des Devel Ther; 2011; 5():255-74. PubMed ID: 21625416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laquinimod therapy in multiple sclerosis: a comprehensive review.
    Kolb-Sobieraj C; Gupta S; Weinstock-Guttman B
    Neurol Ther; 2014 Jun; 3(1):29-39. PubMed ID: 26000222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.